Information Provided By: 
Fly News Breaks for September 11, 2019
EYPT
Sep 11, 2019 | 16:46 EDT
Guggenheim analyst Dana Flanders initiated EyePoint with a Buy rating and a $4 price target, saying a "compelling value proposition should drive strong Dexycu and Yutiq demand," citing improved complicance and favorable reimbursement as advantages over other options. Flanders said that commercial execution should drive EyePoint shares higher, and is also watching for M&A as the company builds its presence.
News For EYPT From the Last 2 Days
There are no results for your query EYPT
